Okayama University Research: Insights Into Mechanisms Governing the Resistance to the Anti-Cancer Medication Cetuximab
Okayama University Research: Insights Into Mechanisms Governing the Resistance to the Anti-Cancer Medication Cetuximab

Okayama University researchers report in Biochemical and Biophysical Research Communications that the anti-cancer drug cetuximab is released with vesicles from cancer cells, findings that may enable the development of...

Global Topical Drugs Market 2018-2022: Market to Grow to a Market Size of More Than $167.2 Billion
Global Topical Drugs Market 2018-2022: Market to Grow to a Market Size of More Than $167.2 Billion

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, Sept 24, 2018 /PRNewswire/ -- The "Global Topical Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offeri...

Arena Pharmaceuticals Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease
Arena Pharmaceuticals Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive topline results from its Phase 2a trial of olorinab, an investigational, peripherally restricted, highly selective, full agonist of the cannabinoid...

Venus Medtech Launches Global Advisor Board to Target for International Market
Venus Medtech Launches Global Advisor Board to Target for International Market

Venus Medtech (Hangzhou) Inc., a Chinese medical device company specializing in transcatheter valve replacement therapy, has retained four world-renowned experts specialized in interventional cardiovascular to form a...

Three Day Drafting Commercial Contracts for the Pharmaceutical Industry Workshop (London, United Kingdom - November 20th-22nd, 2018)
Three Day Drafting Commercial Contracts for the Pharmaceutical Industry Workshop (London, United Kingdom - November 20th-22nd, 2018)

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, Sept 24, 2018 /PRNewswire/ -- The "Drafting Commercial Contracts for the Pharmaceutical Industry" conference has been added to Researc...

Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer
Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that updated phase 1 safety and efficacy data for [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate...

Medical Device Software: Complying with the MDR & FDA Regulations 2018 - Two Day Course - London, United Kingdom - November 20th-21st, 2018
Medical Device Software: Complying with the MDR & FDA Regulations 2018 - Two Day Course - London, United Kingdom - November 20th-21st, 2018

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, Sept 24, 2018 /PRNewswire/ -- The "Medical Device Software: Complying with the MDR & FDA Regulations 2018" conference has been add...

TCT Congress 2018: BIOTRONIK's Orsiro Ultrathin Drug-Eluting Stent Further Outperforms Xience at Two-Year Follow-Up
TCT Congress 2018: BIOTRONIK's Orsiro Ultrathin Drug-Eluting Stent Further Outperforms Xience at Two-Year Follow-Up

Today, BIOTRONIK announced two-year data from the BIOFLOW-V randomized trial comparing the Orsiroa and Xienceb drug-eluting stents (DES). The data shows statistically improved outcomes for patients treated with Orsiro...

Medical Device Report Presents Insights into Resource Allocation Needs in Quality, Regulatory Affairs, and Post-Market Surveillance Roles
Medical Device Report Presents Insights into Resource Allocation Needs in Quality, Regulatory Affairs, and Post-Market Surveillance Roles

Medical device and technology companies devote significant resources to ensure their products meet quality standards and regulations at every stage of the product life cycle, from research and development and product...

Self-Monitoring Blood Glucose Devices Market to Reach $10.82 Bn by 2025 at 4.2% CAGR, Says Allied Market Research
Self-Monitoring Blood Glucose Devices Market to Reach $10.82 Bn by 2025 at 4.2% CAGR, Says Allied Market Research

Rise in prevalence of diabetes, surge in obese & geriatric population, sedentary lifestyle, and technological advancements in diabetes devices would drive the growth of the global self-monitoring blood glucose...

Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...

New Poll: Canadians Strongly Agree that Access to Affordable Prescription Medicines is Most Important Priority for NAFTA 2.0
New Poll: Canadians Strongly Agree that Access to Affordable Prescription Medicines is Most Important Priority for NAFTA 2.0

TORONTO, Sept. 24, 2018 /CNW/ - A new poll confirms that Canadians do not want their access to generic and biosimilar medicines traded away under a new NAFTA deal.

Paradigm Spine Announces Company Activities Highlighting coflex® Interlaminar Stabilization® At NASS Annual Meeting 2018
Paradigm Spine Announces Company Activities Highlighting coflex® Interlaminar Stabilization® At NASS Annual Meeting 2018

Paradigm Spine, LLC, a leader in providing motion preservation solutions for the treatment of lumbar spinal stenosis, today announced its Company activities and scientific podium presentation on coflex® Interlaminar...

Blueprint Medicines Showcases Broad Portfolio of Highly Selective Investigational Kinase Medicines with Presentations at Upcoming Medical Meetings
Blueprint Medicines Showcases Broad Portfolio of Highly Selective Investigational Kinase Medicines with Presentations at Upcoming Medical Meetings

Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the presentation of new clinical and...

Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018
Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the receipt of written guidance from the FDA, confirming concurrence...

DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results
DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the year ended June 30, 2018....

Endo Agrees to Additional Stay of FDA Litigation Following FDA's Commitment to Use Best Efforts to Finalize Vasopressin Clinical Need Determination By Year End
Endo Agrees to Additional Stay of FDA Litigation Following FDA's Commitment to Use Best Efforts to Finalize Vasopressin Clinical Need Determination By Year End

Endo International plc (NASDAQ: ENDP) today announced that it has agreed to an additional stay of its litigation against the U.S. Food and Drug Administration (FDA) until December 31, 2018.   The litigation, filed in the...

Ping An Unveils AI Technology at International Maritime Silk Road Forum
Ping An Unveils AI Technology at International Maritime Silk Road Forum

The second 21st Century Maritime Silk Road Forum on International Communication was held in Zhuhai in 19-21 September. Jean-Pierre Raffarin, former Prime Minister of France and Thomas J. Sargent, the 2011 Nobel Prize...

Cancer Foundation Presents Groundbreaking Study and Solutions at Concordia Summit
Cancer Foundation Presents Groundbreaking Study and Solutions at Concordia Summit

Lazarex Cancer Foundation is presenting a panel on critical issues in cancer today at the Concordia Summit in New York; The Underreported Story of Low Enrollment in Cancer Clinical Trials and How That Holds Back Progress...

Landmark Study Shows Treatment with Abbott's MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation
Landmark Study Shows Treatment with Abbott's MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation

Abbott (NYSE: ABT) today announced positive clinical study results from a randomized controlled trial comparing treatment with the MitraClip® device to guideline-directed medical therapy in select patients with secondary...

Boston Scientific Eluvia Drug-Eluting Stent Demonstrates Superior Results In IMPERIAL Trial
Boston Scientific Eluvia Drug-Eluting Stent Demonstrates Superior Results In IMPERIAL Trial

Today, Boston Scientific (NYSE: BSX) announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral artery (SFA). Results were presented during a...

Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from a Phase 3 clinical study of the investigational product esketamine nasal spray in patients with treatment-resistant depression....

Investigation launched into certain nitisinone capsules from Sweden
Investigation launched into certain nitisinone capsules from Sweden

OTTAWA, Sept. 21, 2018 /CNW/ - The Canada Border Services Agency (CBSA) announced today that it is launching an investigation into whether or not certain nitisinone capsules originating in or exported from Sweden are being...

Digital Transformation in the Pharmaceuticals Industry-Companies-to-Action, 2018 - Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities
Digital Transformation in the Pharmaceuticals Industry-Companies-to-Action, 2018 - Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, Sept 21, 2018 /PRNewswire/ -- The "Digital Transformation in the Pharmaceuticals Industry-Companies-to-Action, 2018" report has been a...

AlloSource Named One Of The 100 Healthiest Workplaces In America By Healthiest Employers
AlloSource Named One Of The 100 Healthiest Workplaces In America By Healthiest Employers

AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, today announced that Healthiest Employers® named AlloSource one of the 100 Healthiest Workplaces in...

Global DNA Vaccine Market Outlook 2018-2022: Increasing Investment, Dramatic Increase in Chronic Disorders, Strong DNA Vaccine Pipeline & Technological Advancements
Global DNA Vaccine Market Outlook 2018-2022: Increasing Investment, Dramatic Increase in Chronic Disorders, Strong DNA Vaccine Pipeline & Technological Advancements

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com SOURCE Research and Markets DUBLIN, Sept 21, 2018 /PRNewswire/ -- The "Global DNA Vaccine Market Outlook 2022" report has been added to ResearchAndMarkets.com's offer...

Rhode Island Headlines 

Massachusetts Headlines 

National